TNFR1 inhibitor - Arcus Biosciences
Latest Information Update: 13 Nov 2025
At a glance
- Originator Arcus Biosciences
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis